217 related articles for article (PubMed ID: 17466373)
1. Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells.
Kimura N; Miyakawa Y; Kohmura K; Umezawa K; Ikeda Y; Kizaki M
Leuk Res; 2007 Nov; 31(11):1529-35. PubMed ID: 17466373
[TBL] [Abstract][Full Text] [Related]
2. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Starenki DV; Namba H; Saenko VA; Ohtsuru A; Maeda S; Umezawa K; Yamashita S
Clin Cancer Res; 2004 Oct; 10(20):6821-9. PubMed ID: 15501958
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
Lampiasi N; Azzolina A; D'Alessandro N; Umezawa K; McCubrey JA; Montalto G; Cervello M
Mol Pharmacol; 2009 Aug; 76(2):290-300. PubMed ID: 19461054
[TBL] [Abstract][Full Text] [Related]
4. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.
Ruan HY; Masuda M; Ito A; Umezawa K; Nakashima T; Yasumatsu R; Kuratomi Y; Yamamoto T; Weinstein IB; Komune S
Head Neck; 2006 Feb; 28(2):158-65. PubMed ID: 16355386
[TBL] [Abstract][Full Text] [Related]
5. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
[TBL] [Abstract][Full Text] [Related]
6. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
Nishimura D; Ishikawa H; Matsumoto K; Shibata H; Motoyoshi Y; Fukuta M; Kawashimo H; Goto T; Taura N; Ichikawa T; Hamasaki K; Nakao K; Umezawa K; Eguchi K
Int J Oncol; 2006 Sep; 29(3):713-9. PubMed ID: 16865289
[TBL] [Abstract][Full Text] [Related]
7. Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ).
Horiuchi K; Morioka H; Nishimoto K; Suzuki Y; Susa M; Nakayama R; Kawai A; Sonobe H; Takaishi H; Ozaki T; Yabe H; Umezawa K; Toyama Y
Cancer Lett; 2008 Dec; 272(2):336-44. PubMed ID: 18760530
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-kappaB inhibitor.
Matsumoto G; Muta M; Umezawa K; Suzuki T; Misumi K; Tsuruta K; Okamoto A; Toi M
Int J Oncol; 2005 Nov; 27(5):1247-55. PubMed ID: 16211219
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production.
Poma P; Notarbartolo M; Labbozzetta M; Sanguedolce R; Alaimo A; Carina V; Maurici A; Cusimano A; Cervello M; D'Alessandro N
Int J Oncol; 2006 Apr; 28(4):923-30. PubMed ID: 16525642
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells.
Horiguchi Y; Kuroda K; Nakashima J; Murai M; Umezawa K
Expert Rev Anticancer Ther; 2003 Dec; 3(6):793-8. PubMed ID: 14686701
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Suzuki E; Umezawa K
Biomed Pharmacother; 2006 Nov; 60(9):578-86. PubMed ID: 16978829
[TBL] [Abstract][Full Text] [Related]
12. A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells.
Wong JH; Lui VW; Umezawa K; Ho Y; Wong EY; Ng MH; Cheng SH; Tsang CM; Tsao SW; Chan AT
Cancer Lett; 2010 Jan; 287(1):23-32. PubMed ID: 19560263
[TBL] [Abstract][Full Text] [Related]
13. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
[TBL] [Abstract][Full Text] [Related]
14. Blocking NF-kappaB as a potential strategy to treat adult T-cell leukemia/lymphoma.
Horie R; Watanabe T; Umezawa K
Drug News Perspect; 2006 May; 19(4):201-9. PubMed ID: 16823495
[TBL] [Abstract][Full Text] [Related]
15. In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia.
Ohsugi T; Horie R; Kumasaka T; Ishida A; Ishida T; Yamaguchi K; Watanabe T; Umezawa K; Urano T
Carcinogenesis; 2005 Aug; 26(8):1382-8. PubMed ID: 15831528
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of inflammatory cytokine secretion from mouse microglia cells by DHMEQ, an NF-kappaB inhibitor.
Takatsuna H; Morita S; Nagatsu T; Sawada M; Umezawa K
Biomed Pharmacother; 2005 Jul; 59(6):318-22. PubMed ID: 15932789
[TBL] [Abstract][Full Text] [Related]
17. Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines.
Ohsugi T; Kumasaka T; Okada S; Ishida T; Yamaguchi K; Horie R; Watanabe T; Umezawa K
Cancer Lett; 2007 Nov; 257(2):206-15. PubMed ID: 17764832
[TBL] [Abstract][Full Text] [Related]
18. DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts.
Makino S; Mitsutake N; Nakashima M; Saenko VA; Ohtsuru A; Umezawa K; Tanaka K; Hirano A; Yamashita S
J Dermatol Sci; 2008 Sep; 51(3):171-80. PubMed ID: 18406579
[TBL] [Abstract][Full Text] [Related]
19. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent.
Katsman A; Umezawa K; Bonavida B
Drug Resist Updat; 2007; 10(1-2):1-12. PubMed ID: 17306602
[TBL] [Abstract][Full Text] [Related]
20. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells.
Wakamatsu K; Nanki T; Miyasaka N; Umezawa K; Kubota T
Arthritis Res Ther; 2005; 7(6):R1348-59. PubMed ID: 16277688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
